Proteasome inhibitors suppress the protein expression of mutant p53

References

• Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9:749-58; PMID:19776744; http://dx.doi.org/10.1038/nrc2723
   PubMed Web of Science ®Google Scholar
• Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10:1054-72; PMID:8654922; http://dx.doi.org/10.1101/gad.10.9.1054
   PubMed Web of Science ®Google Scholar
• Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 1991; 65:1083-91; PMID:1646078; http://dx.doi.org/10.1016/0092-8674(91)90560-L
   PubMed Web of Science ®Google Scholar
• Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 1992; 12:2866-71; PMID:1588974
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-9; PMID:7834749; http://dx.doi.org/10.1016/0092-8674(95)90412-3
   PubMed Web of Science ®Google Scholar
• Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7:683-94; PMID:11463392; http://dx.doi.org/10.1016/S1097-2765(01)00214-3
   PubMed Web of Science ®Google Scholar
• Chao C, Saito S, Kang J, Anderson CW, Appella E, Xu Y. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. Embo J 2000; 19:4967-75; PMID:10990460; http://dx.doi.org/10.1093/emboj/19.18.4967
   PubMed Web of Science ®Google Scholar
• Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994; 54:2095-7; PMID:8174112
   PubMed Web of Science ®Google Scholar
• Innocente SA, Abrahamson JL, Cogswell JP, Lee JM. p53 regulates a G2 checkpoint through cyclin B1. Proc Natl Acad Sci U S A 1999; 96:2147-52; PMID:10051609; http://dx.doi.org/10.1073/pnas.96.5.2147
   PubMed Web of Science ®Google Scholar
• Pandit B, Halasi M, Gartel AL. p53 negatively regulates expression of FoxM1. Cell Cycle 2009; 8:3425-7; PMID:19806025; http://dx.doi.org/10.4161/cc.8.20.9628
   PubMed Web of Science ®Google Scholar
• Mirza A, Wu Q, Wang L, McClanahan T, Bishop WR, Gheyas F, Ding W, Hutchins B, Hockenberry T, Kirschmeier P, et al. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 2003; 22:3645-54; PMID:12789273; http://dx.doi.org/10.1038/sj.onc.1206477
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV, Demidenko ZN, Fojo T. Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: p53 as a sensor of transcriptional integrity. Cell Cycle 2002; 1:67-74; PMID:12429911
   PubMed Web of Science ®Google Scholar
• Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003; 13:49-58; PMID:12507556; http://dx.doi.org/10.1016/S1044-579X(02)00099-8
   PubMed Web of Science ®Google Scholar
• Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11:577-90; PMID:12667443; http://dx.doi.org/10.1016/S1097-2765(03)00050-9
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53; PMID:1905840; http://dx.doi.org/10.1126/science.1905840
   PubMed Web of Science ®Google Scholar
• Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sørensen B, Montesano R, Harris CC. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994; 22:3551-5; PMID:7937055
   PubMed Web of Science ®Google Scholar
• Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013; 23:634-46; PMID:23680148; http://dx.doi.org/10.1016/j.ccr.2013.03.022
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Loss of function and p53 protein stabilization. Oncogene 1997; 15:1889-93; PMID:9365234; http://dx.doi.org/10.1038/sj.onc.1201374
   PubMed Web of Science ®Google Scholar
• Farnebo M, Bykov VJ, Wiman KG. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 2010; 396:85-9; PMID:20494116; http://dx.doi.org/10.1016/j.bbrc.2010.02.152
   PubMed Web of Science ®Google Scholar
• Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1:68-76; PMID:11900253; http://dx.doi.org/10.1038/35094077
   PubMed Web of Science ®Google Scholar
• Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8:282-8; PMID:11875500; http://dx.doi.org/10.1038/nm0302-282
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-22; PMID:10363983
   PubMed Web of Science ®Google Scholar
• Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002; 16:433-43; PMID:11960320; http://dx.doi.org/10.1038/sj.leu.2402417
   PubMed Web of Science ®Google Scholar
• An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000; 14:1276-83; PMID:10914553
   PubMed Web of Science ®Google Scholar
• Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011; 20:79-91; PMID:21741598; http://dx.doi.org/10.1016/j.ccr.2011.06.004
   PubMed Web of Science ®Google Scholar
• Yoshikawa H, Nagashima M, Khan MA, McMenamin MG, Hagiwara K, Harris CC. Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene 1999; 18:3415-21; PMID:10362363; http://dx.doi.org/10.1038/sj.onc.1202677
   PubMed Web of Science ®Google Scholar
• Bajgelman MC, Strauss BE. The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53. Prostate 2006; 66:1455-62; PMID:16741917; http://dx.doi.org/10.1002/pros.20462
   PubMed Web of Science ®Google Scholar
• Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD, Habtemariam B, Bullock J, Bray JD, Hawes J, et al. U S Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013; 19:4559-63; PMID:23775332; http://dx.doi.org/10.1158/1078-0432.CCR-13-0755
   PubMed Web of Science ®Google Scholar
• Bhat UG, Halasi M, Gartel AL. FoxM1 is a general target for proteasome inhibitors. PLoS One 2009; 4:e6593; PMID:19672316; http://dx.doi.org/10.1371/journal.pone.0006593
   PubMed Web of Science ®Google Scholar
• Yan W, Zhang Y, Zhang J, Liu S, Cho SJ, Chen X. Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression. J Biol Chem 2011; 286:17478-86; PMID:21454520; http://dx.doi.org/10.1074/jbc.M111.231639
   PubMed Web of Science ®Google Scholar
• Radhakrishnan SK, Gierut J, Gartel AL. Multiple alternate p21 transcripts are regulated by p53 in human cells. Oncogene 2006; 25:1812-5; PMID:16261158; http://dx.doi.org/10.1038/sj.onc.1209195
   PubMed Web of Science ®Google Scholar
• An WG, Chuman, Y., Fojo, T., Blagosklonny, MV. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. Exp Cell Res 1998; 244:54-60; PMID:9770348; http://dx.doi.org/10.1006/excr.1998.4193
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J 2000; 14:1901-7; PMID:11023974; http://dx.doi.org/10.1096/fj.99-1078rev
   PubMed Web of Science ®Google Scholar
• Aldoss I, Mark L, Vrona J, Ramezani L, Weitz I, Mohrbacher AM, Douer D. Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia. Ann Hematol 2014; PMID:24906216
   PubMed Web of Science ®Google Scholar
• Gartel AL. Thiostrepton, proteasome inhibitors and FOXM1. Cell Cycle 2011; 10:4341-2; PMID:22134246; http://dx.doi.org/10.4161/cc.10.24.18544
   PubMed Web of Science ®Google Scholar
• Halasi M, Gartel AL. A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell Cycle 2009; 8:1966-7; PMID:19411834; http://dx.doi.org/10.4161/cc.8.12.8708
   PubMed Web of Science ®Google Scholar
• Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, Gartel AL. Identification of a Chemical Inhibitor of the Oncogenic Transcription Factor Forkhead Box M1. Cancer Res 2006; 66:9731-35; PMID:17018632; http://dx.doi.org/10.1158/0008-5472.CAN-06-1576
   PubMed Web of Science ®Google Scholar
• Major ML, Lepe R, Costa RH. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol Cell Biol 2004; 24:2649-61; PMID:15024056; http://dx.doi.org/10.1128/MCB.24.7.2649-2661.2004
   PubMed Web of Science ®Google Scholar